Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK kava ban “folly”

This article was originally published in The Tan Sheet

Executive Summary

National Institute of Medical Herbalists condemns UK decision to ban kava as "pure folly," noting Medicines Control Agency ruling "is totally at odds with the evidence available...[and] will harm more patients than it's supposed to protect." In 1Jan. 13 NIMH release, group maintains previous cases of liver toxicity linked to kava "have referred to the use of concentrated extracts rather than the safe traditional use of the herb." Group has started petition and letter-writing campaign to encourage MCA to remove kava ban now in effect (2"The Tan Sheet" Jan. 6, 2003, In Brief)...

You may also be interested in...

Kava banned in UK

Order prohibiting sale, supply, import of kava medicinal products will take effect in UK on January 13, Medicines Control Agency announces. Following examination of 70 reports of adverse liver reactions due to kava consumption - four cases resulting in death, seven in transplants - MCA "concluded that there is clear evidence linking kava...with rare cases of liver disease." However, agency notes it will review the ban in two years to assess whether it remains justified, and can review decision "at any time if new evidence emerges." The UK dietary supplement industry initially agreed to pull kava supplements from store shelves in December 2001 (1"The Tan Sheet" Dec. 24, 2001, p. 14)...

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts